Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
73.3M
-
Shares change
-
+6.59M
-
Total reported value, excl. options
-
$457M
-
Value change
-
+$38.8M
-
Put/Call ratio
-
0.24
-
Number of buys
-
91
-
Number of sells
-
-62
-
Price
-
$6.23
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q4 2022
211 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2022.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73.3M shares
of 207M outstanding shares and own 35.35% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS INC (6.85M shares), BlackRock Inc. (5.51M shares), Meditor Group Ltd (4.47M shares), Bellevue Group AG (4.33M shares), VANGUARD GROUP INC (4.26M shares), Deep Track Capital, LP (4M shares), Balyasny Asset Management LLC (3.43M shares), BRAIDWELL LP (3.39M shares), Point72 Asset Management, L.P. (2.28M shares), and MILLENNIUM MANAGEMENT LLC (2.23M shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.